Thursday, April 08, 2021 2:19:12 AM
In re K.Power
As I understand, she is based in Edmonton. Why would someone in Edmonton be hired by NWBO? Why not in Toronto or Ottawa? Why a CFA? Why now? The whole thing made little sense to me and market reaction was nil.
What does Edmonton offer that might be of any value or attraction to NWBO?
Well, it so happens that there are a number of pharma companies there. For example, there is Quest PharmaTech listed on the TSXV. Relatively small company. It makes equity investments. One such investment is in OncoQuest Inc. which is developing an antibody based immunotherapeutic product for cancer. It recently entered into an asset transfer agreement with Korean based OncoQuest Pharmaceuticals for USD 300 million and holds a 45% ownership share. It has made other various investments in cancer development projects including pancreatic cancer in China and the US.
Another pharma company is Gilead Alberta.
There are also about 150 investment funds based in Edmonton. FWIW.
As I understand, she is based in Edmonton. Why would someone in Edmonton be hired by NWBO? Why not in Toronto or Ottawa? Why a CFA? Why now? The whole thing made little sense to me and market reaction was nil.
What does Edmonton offer that might be of any value or attraction to NWBO?
Well, it so happens that there are a number of pharma companies there. For example, there is Quest PharmaTech listed on the TSXV. Relatively small company. It makes equity investments. One such investment is in OncoQuest Inc. which is developing an antibody based immunotherapeutic product for cancer. It recently entered into an asset transfer agreement with Korean based OncoQuest Pharmaceuticals for USD 300 million and holds a 45% ownership share. It has made other various investments in cancer development projects including pancreatic cancer in China and the US.
Another pharma company is Gilead Alberta.
There are also about 150 investment funds based in Edmonton. FWIW.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
